BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock.

Barinthus Biotherapeutics plc (NASDAQ: BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024.

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease - scientists have classified hundreds of types and found a myriad of genetic drivers underlying them.

CG Oncology, Inc. today announced the publication in Nature Medicine of final results from the Company’s CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NIMBC).

Medtronic plc, a global leader in healthcare technology, announced it will participate in the 45th annual Goldman Sachs global healthcare conference on Tuesday, June 11, 2024.

Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”

Scilex Holding Company announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment of €188 million led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne.

Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction.

Agomab Therapeutics NV announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration for AGMB-447, its inhaled, small molecule inhibitor of ALK5.